CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib

Mantle cell lymphoma (MCL) is a rare subtype of non‐Hodgkin's lymphoma, which is characterized by overexpression of cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed MCL often acquires drug resistance. Therefore, alternative approaches for refractory...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Sci
Main Authors: Kagiyama, Yuki, Fujita, Shuhei, Shima, Yutaka, Yamagata, Kazutsune, Katsumoto, Takuo, Nakagawa, Makoto, Honma, Daisuke, Adachi, Nobuaki, Araki, Kazushi, Kato, Ayako, Inaki, Koichiro, Ono, Yoshimasa, Fukuhara, Suguru, Kobayashi, Yukio, Tobinai, Kensei, Kitabayashi, Issay
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2021
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177787/
https://ncbi.nlm.nih.gov/pubmed/33792119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14905
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items